IL249925B - Immunogenic products based on amino acid sequences mutine amyloid beta (abeta) and their uses - Google Patents
Immunogenic products based on amino acid sequences mutine amyloid beta (abeta) and their usesInfo
- Publication number
- IL249925B IL249925B IL249925A IL24992517A IL249925B IL 249925 B IL249925 B IL 249925B IL 249925 A IL249925 A IL 249925A IL 24992517 A IL24992517 A IL 24992517A IL 249925 B IL249925 B IL 249925B
- Authority
- IL
- Israel
- Prior art keywords
- abeta
- mutein
- amino acid
- acid sequences
- amyloid beta
- Prior art date
Links
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 title 1
- 230000002163 immunogen Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462021308P | 2014-07-07 | 2014-07-07 | |
| PCT/EP2015/065362 WO2016005328A2 (en) | 2014-07-07 | 2015-07-06 | IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID ß (Aß) AMINO ACID SEQUENCES AND USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL249925A0 IL249925A0 (en) | 2017-03-30 |
| IL249925B true IL249925B (en) | 2021-09-30 |
Family
ID=53525183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL249925A IL249925B (en) | 2014-07-07 | 2017-01-04 | Immunogenic products based on amino acid sequences mutine amyloid beta (abeta) and their uses |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20160000891A1 (enExample) |
| EP (1) | EP3166969A2 (enExample) |
| JP (3) | JP2017532289A (enExample) |
| CN (1) | CN107074924A (enExample) |
| AU (2) | AU2015286824A1 (enExample) |
| CA (1) | CA2954031A1 (enExample) |
| IL (1) | IL249925B (enExample) |
| MX (1) | MX2017000094A (enExample) |
| RU (1) | RU2750268C2 (enExample) |
| SG (1) | SG11201700071WA (enExample) |
| WO (1) | WO2016005328A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101667623B1 (ko) | 2005-11-30 | 2016-10-19 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
| CN102933601B (zh) * | 2010-04-15 | 2016-06-08 | Abbvie公司 | β淀粉样蛋白结合蛋白 |
| CN103298833B (zh) | 2010-08-14 | 2015-12-16 | Abbvie公司 | β淀粉样蛋白结合蛋白 |
| CA2954031A1 (en) * | 2014-07-07 | 2016-01-14 | AbbVie Deutschland GmbH & Co. KG | Immunogenic products based on mutein amyloid .beta. (.alpha..beta.) amino acid sequences and uses thereof |
| JP7007278B2 (ja) * | 2016-09-06 | 2022-02-10 | 富士レビオ株式会社 | サイログロブリンの測定方法及び測定試薬 |
| EP3514539B1 (en) * | 2016-09-13 | 2024-11-20 | Fujirebio Inc. | Cardiac troponin assay method and assay reagent |
| KR20210052389A (ko) | 2018-08-27 | 2021-05-10 | 리제너론 파마슈티칼스 인코포레이티드 | 다운스트림 정제에서의 라만 분광법의 사용 |
| CN110412294B9 (zh) * | 2019-08-07 | 2023-05-26 | 深圳市新产业生物医学工程股份有限公司 | 蛋白稳定液、蛋白校准品、试剂盒及检测蛋白校准品稳定性的方法 |
| WO2021055670A1 (en) | 2019-09-20 | 2021-03-25 | Avx Corporation | Somatic cell-based electrical biosensor |
| CN112851786B (zh) * | 2019-11-12 | 2022-11-15 | 深圳市新产业生物医学工程股份有限公司 | 可溶性的Aβ1-42变体、Aβ1-42校准品及试剂盒 |
| CN111793131A (zh) * | 2020-05-11 | 2020-10-20 | 廊坊天光生物技术有限公司 | 一种用于检测血清中pf4含量的抗体对及其用途 |
| EP4286405A4 (en) * | 2021-01-28 | 2025-03-19 | Abrain | GENE THERAPY FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES |
| EP4230645A1 (en) * | 2022-02-22 | 2023-08-23 | Technische Universität München | Peptidic inhibitors of amyloid self- and cross-assembly |
| CN117700525B (zh) * | 2024-02-05 | 2024-06-18 | 上海良润生物医药科技有限公司 | 一种多肽改造体及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| KR20080090408A (ko) * | 2005-11-30 | 2008-10-08 | 아보트 러보러터리즈 | 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법 |
| US20110092445A1 (en) * | 2008-07-25 | 2011-04-21 | Abbott Laboratories | Amyloid ß peptide analogues, oligomers thereof, processes for preparing and composi-tions comprising said analogues or oligomers, and their uses |
| CN102933601B (zh) * | 2010-04-15 | 2016-06-08 | Abbvie公司 | β淀粉样蛋白结合蛋白 |
| CN103298833B (zh) * | 2010-08-14 | 2015-12-16 | Abbvie公司 | β淀粉样蛋白结合蛋白 |
| CA2954031A1 (en) * | 2014-07-07 | 2016-01-14 | AbbVie Deutschland GmbH & Co. KG | Immunogenic products based on mutein amyloid .beta. (.alpha..beta.) amino acid sequences and uses thereof |
-
2015
- 2015-07-06 CA CA2954031A patent/CA2954031A1/en active Pending
- 2015-07-06 WO PCT/EP2015/065362 patent/WO2016005328A2/en not_active Ceased
- 2015-07-06 CN CN201580047718.9A patent/CN107074924A/zh active Pending
- 2015-07-06 RU RU2017103527A patent/RU2750268C2/ru active
- 2015-07-06 AU AU2015286824A patent/AU2015286824A1/en not_active Abandoned
- 2015-07-06 JP JP2017500952A patent/JP2017532289A/ja active Pending
- 2015-07-06 EP EP15735674.2A patent/EP3166969A2/en not_active Withdrawn
- 2015-07-06 SG SG11201700071WA patent/SG11201700071WA/en unknown
- 2015-07-06 US US14/792,500 patent/US20160000891A1/en not_active Abandoned
- 2015-07-06 MX MX2017000094A patent/MX2017000094A/es unknown
-
2017
- 2017-01-04 IL IL249925A patent/IL249925B/en unknown
-
2020
- 2020-09-18 JP JP2020156999A patent/JP2021001203A/ja active Pending
-
2021
- 2021-01-29 AU AU2021200575A patent/AU2021200575A1/en not_active Abandoned
-
2022
- 2022-10-27 US US18/050,314 patent/US20240075114A1/en active Pending
- 2022-12-01 JP JP2022192713A patent/JP2023036606A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2017103527A (ru) | 2018-08-07 |
| EP3166969A2 (en) | 2017-05-17 |
| JP2023036606A (ja) | 2023-03-14 |
| RU2750268C2 (ru) | 2021-06-25 |
| CA2954031A1 (en) | 2016-01-14 |
| BR112017000428A2 (pt) | 2017-10-31 |
| AU2021200575A1 (en) | 2021-03-04 |
| WO2016005328A3 (en) | 2016-05-26 |
| US20160000891A1 (en) | 2016-01-07 |
| MX2017000094A (es) | 2017-04-27 |
| WO2016005328A2 (en) | 2016-01-14 |
| IL249925A0 (en) | 2017-03-30 |
| CN107074924A (zh) | 2017-08-18 |
| RU2017103527A3 (enExample) | 2019-02-19 |
| AU2015286824A1 (en) | 2017-02-09 |
| US20240075114A1 (en) | 2024-03-07 |
| JP2021001203A (ja) | 2021-01-07 |
| SG11201700071WA (en) | 2017-02-27 |
| JP2017532289A (ja) | 2017-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL249925A0 (en) | Immunogenic products based on amino acid sequences mutine amyloid beta (abeta) and their uses | |
| IL286265A (en) | A new tilapia virus and its uses | |
| IL246978A0 (en) | New paracetamol formulations | |
| ZA201608682B (en) | Boronic acid derivatives and therapeutic uses thereof | |
| IL251571A0 (en) | Variable proteins comprising the cry1da1 amino acid sequence are activated by lepidopteran | |
| IL246757A0 (en) | New insulin histories and their medical uses | |
| IL246774B (en) | Sterile chromatography and manufacturing processes | |
| PL3157901T3 (pl) | Preparaty, ich wytwarzanie i zastosowanie, oraz odpowiednie składniki | |
| IL275435A (en) | TATK – CDKL5 fusion proteins, preparations, formulations, and their uses | |
| GB2560275B (en) | Event driven subscription matching | |
| SG10201506617QA (en) | Components with multiple energization elements for biomedical devices | |
| EP3118191A4 (en) | Aniline derivative and use thereof | |
| EP3203177A4 (en) | Solution conveying and cooling device | |
| IL252902A0 (en) | Amino acid and peptide conjugates and their uses | |
| EP3118190A4 (en) | Aniline derivative and use thereof | |
| GB201404569D0 (en) | Cyclopropene amino acids and methods | |
| IL251656A0 (en) | The compositions containing tiotropium, amino acid and acid and methods thereof | |
| IL251289A0 (en) | New peptide derivatives and their use | |
| EP3176150A4 (en) | Medium-chain acyl basic amino acid derivative | |
| EP3118187A4 (en) | Aniline derivative and use thereof | |
| GB201417589D0 (en) | Pharmaceutical Formulations | |
| GB201406838D0 (en) | High di/dt superconductive joint | |
| ZA201608886B (en) | Human cytolytic fusion proteins | |
| GB201403903D0 (en) | Vesicular formulations and uses thereof | |
| GB201403884D0 (en) | Vesicular formulations and uses thereof |